Chimerix Inc
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a sec… Read more
Chimerix Inc (CMRX) - Total Assets
Latest total assets as of March 2025: $146.01 Million USD
Based on the latest financial reports, Chimerix Inc (CMRX) holds total assets worth $146.01 Million USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Chimerix Inc - Total Assets Trend (2011–2024)
This chart illustrates how Chimerix Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Chimerix Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Chimerix Inc's total assets of $146.01 Million consist of 93.1% current assets and 6.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.3% |
| Accounts Receivable | $812.00K | 0.6% |
| Inventory | $-2.41 Million | -1.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Chimerix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chimerix Inc's current assets represent 93.1% of total assets in 2024, a decrease from 97.6% in 2011.
- Cash Position: Cash and equivalents constituted 21.3% of total assets in 2024, down from 53.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Chimerix Inc Competitors by Total Assets
Key competitors of Chimerix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Chimerix Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Chimerix Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Chimerix Inc is currently not profitable relative to its asset base.
Chimerix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.70 | 8.61 | 15.86 |
| Quick Ratio | 5.70 | 8.61 | 15.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $112.08 Million | $ 144.10 Million | $ 92.66 Million |
Chimerix Inc - Advanced Valuation Insights
This section examines the relationship between Chimerix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.58 |
| Latest Market Cap to Assets Ratio | 4.70 |
| Asset Growth Rate (YoY) | -31.4% |
| Total Assets | $146.01 Million |
| Market Capitalization | $686.96 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Chimerix Inc's assets at a significant premium ( 4.70x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Chimerix Inc's assets decreased by 31.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Chimerix Inc (2011–2024)
The table below shows the annual total assets of Chimerix Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $146.01 Million | -31.38% |
| 2023-12-31 | $212.77 Million | -23.83% |
| 2022-12-31 | $279.34 Million | +177.84% |
| 2021-12-31 | $100.54 Million | +18.67% |
| 2020-12-31 | $84.72 Million | -29.03% |
| 2019-12-31 | $119.38 Million | -37.41% |
| 2018-12-31 | $190.71 Million | -18.92% |
| 2017-12-31 | $235.23 Million | -17.97% |
| 2016-12-31 | $286.77 Million | -19.44% |
| 2015-12-31 | $355.99 Million | +21.97% |
| 2014-12-31 | $291.88 Million | +157.42% |
| 2013-12-31 | $113.39 Million | +253.99% |
| 2012-12-31 | $32.03 Million | +25.95% |
| 2011-12-31 | $25.43 Million | -- |